Ovid reports Takeda's Ph3 soticlestat misses primary endpoints; pipeline and cash runway update

Ovid Therapeutics Inc.

Takeda's Phase 3 SKYLINE in Dravet syndrome narrowly missed primary endpoint (p=0.06) but showed significant secondary endpoints (p≤0.008).
Takeda's Phase 3 SKYWAY in Lennox-Gastaut syndrome missed primary endpoint; safety profile consistent.
Ovid's cash runway expected into H1 2026; pipeline milestones include OV888 Phase 2 start H2 2024, OV329 data H2 2024, OV350 IND H2 2024.
Takeda will discuss data with regulators; Ovid will update guidance on potential milestones/royalties afterward.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.